CAS 129938-20-1 Sex Enhancing Drugs Muscle Gain Hydrochloride

Muscle Gain Hydrochloride Sex Enhancing Drugs CAS 129938-20-1

Basic information:

Detailed information:

, marketed as Priligy and Westoxetin, among and other brands, is the first compound developed specially for the treatment of premature ejaculation (PE) in men 18–64 years old.[2][3] works by inhibiting the serotonin transporter, increasing serotonin's action at the post synaptic cleft, and as a consequence promoting ejaculatory delay. As a member of selective serotonin reuptake inhibitor (SSRI) family, was initially created as an antidepressant. However, unlike other SSRIs, is absorbed and eliminated rapidly in the body. Its fast acting property makes it suitable for the treatment of PE but not as an antidepressant.
Originally created by Eli Lilly pharmaceutical company, was sold to Johnson & Johnson in 2003 and submitted as a New Drug Application to the Food and Drug Administration (FDA) for the treatment of PE in 2004. is sold in several European and Asian countries, and in Mexico. In the US, has been in phase III development since 2003. However, it is expected to be marketed soon. In 2012, Menarini acquired the rights to commercialise in Europe, most of Asia, Africa, Latin America and the Middle East. 

Randomized, double blind, placebo-controlled trials have confirmed the efficacy of for the treatment of PE. Different dosage has different impacts on different type of PE. 60 mg significantly improves the mean intravaginal ejaculation latency time (IELT) compared to that of 30 mg in men with lifelong PE, but there is no difference in men with acquired PE.[9] , given 1–3 hours before sexual episode, prolongs IELT, increases the sense of control and sexual satisfaction in men of 18 to 64 years of age with PE. Since PE is associated with personal distress, interrelationship difficulty, provides help for men with PE to overcome this condition.[10] Because lack of specific approval treatment for PE in the US and some other countries, other SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, and citalopram have been used as off label drugs to treat PE. Waldinger's meta analysis shows that the use of these conventional antidepressants increasing IELT from two to ninefold above base line in comparison of three to eightfold when is used. However, these SSRIs must be taken daily in order to achieve meaningful efficacy, and the long half-life increases the risk of the drug accumulation and as a consequence increased of adverse effects such as decreasing sexual libido and causing erectile dysfunction. , on the other hand, is a fast-acting SSRI. It is rapidly absorbed and eliminated from the body within a few hours. This favorable pharmacokinetics minimizes the risk of the drug's accumulation in the body, and therefore reducing side effects.

Application:

was created by Eli Lilly and in phase I clinical trial as an antidepressant. However, It never worked out well as a medication for the treatment of depression and was shelved for a while before subsequently developed to treat PE. In December 2003, Eli Lilly sold patent of to Pharmaceutical Product Development(PPD) for 65 million US dollars in cash. Eli Lilly may also receive royalties payment from PPD if the sale exceeds certain amount.
ALZA is the current owner of . However, PPD will receive milestone payment and drug royalties from ALZA. If approved, will be marketed in the US by Ortho McNeil pharmaceutical, Inc. Ortho McNeil as well as Janssen-Ortho Inc, or Janssen-Cilag are all units of Johnson & Johnson. is currently in phase III clinical trials, pending review by the Federal Drug Administration (FDA).[34]
has been marketed and approved in more than 50 countries.[35] has been approved in Italy, Spain, Mexico, South Korea, and New Zealand in 2009 and 2010; marketed in Sweden, Austria, Germany, Finland, Spain, Portugal, and Italy. It has also been approved in France, Russia, Malaysia, Philippines, Argentina, and Uruguay.

Other related products: